Aerovate Therapeutics, Inc.
AVTE
$0.06
Change (1 day)
$32.42
Year High
$1.25
Year Low
Categories
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
P/B ratio for Aerovate Therapeutics, Inc. (AVTE)
P/B ratio as of 2023: 5.44
According to Aerovate Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.44. At the end of 2022 the company had a P/B ratio of 5.66.
P/B ratio history for Aerovate Therapeutics, Inc. from 2019 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 5.44 |
| 2022 | 5.66 |
| 2021 | 1.67 |
| 2020 | -41.76 |
| 2019 | -152.98 |